Morgan Stanley downgraded Peloton to Underweight from Equal-weight and cut its price target to $4.50 from $5.50, while UBS retained its Buy rating but reduced its target to $10.00 from $11.00. Peloton shares fell as much as 6.1% in premarket trading to $5.07. Lead analyst Nathan Feather said customer-acquisition weakness and a 9% year-over-year decline in connected-fitness subscribers during fiscal 2026 reflected structural changes in consumer fitness preferences, rather than cyclical pressure. New additions have fallen about 78% from their peak, and Morgan Stanley expects negative subscriber growth rates through fiscal 2029. UBS also cut its fiscal 2027 EBITDA forecast to $491 million from $526 million, citing higher-than-expected subscriber churn. Feather pointed to rising interest in strength training and gym memberships as challenges for Peloton’s cardio-focused, at-home model. Six executives sold shares over the past three months, with no insider purchases recorded, while short interest stood at 14.4% of available shares.